Carna Biosciences, Inc. Logo

Carna Biosciences, Inc.

Develops kinase inhibitor drugs for oncology/autoimmune diseases & offers discovery support services.

4572 | T

Overview

Corporate Details

ISIN(s):
JP3220550002
LEI:
Country:
Japan
Address:
神戸市中央区港島南町一丁目5番5号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company founded in 2003, specializing in the discovery and development of innovative kinase inhibitor drugs. The company focuses on creating small molecule therapies to address unmet medical needs in oncology, autoimmune diseases, and neurodegenerative disorders. Carna Biosciences operates a dual business model: advancing its proprietary drug pipeline for out-licensing and providing comprehensive drug discovery support services. These services include the manufacturing of kinase proteins, as well as offering profiling, screening, and assay development to support pharmaceutical and biotechnology research globally. The company leverages its deep expertise in kinase biology to develop novel therapeutic candidates.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 07:45
Registration Form
訂正有価証券届出書(組込方式)
Japanese 347.4 KB
2025-09-12 08:46
Registration Form
訂正有価証券届出書(組込方式)
Japanese 325.6 KB
2025-08-07 02:46
Registration Form
訂正有価証券届出書(組込方式)
Japanese 243.9 KB
2025-08-07 02:45
Registration Form
訂正有価証券届出書(組込方式)
Japanese 244.0 KB
2025-08-07 02:43
Interim Report
確認書
Japanese 8.8 KB
2025-08-07 02:42
Interim Report
半期報告書-第23期(2025/01/01-2025/12/31)
Japanese 358.3 KB
2025-07-11 08:47
Registration Form
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:46
Registration Form
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:45
Registration Form
有価証券届出書(組込方式)
Japanese 392.8 KB
2025-03-28 02:41
Regulatory News Service
臨時報告書
Japanese 28.5 KB
2025-03-26 02:11
Governance Information
内部統制報告書-第22期(2024/01/01-2024/12/31)
Japanese 24.5 KB
2025-03-26 02:10
Registration Form
確認書
Japanese 8.7 KB
2025-03-26 02:08
Annual Report
有価証券報告書-第22期(2024/01/01-2024/12/31)
Japanese 1.3 MB
2024-09-25 08:39
Share Issue/Capital Change
臨時報告書
Japanese 122.5 KB
2024-08-08 02:51
Report Publication Announcement
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Carna Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Carna Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Carna Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.